Zepbound beats Wegovy for weight loss - Search News

Order byBest matchMost fresh

News

Zepbound, Trial and Weight Loss

Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) over 72 weeks, while those who took semaglutide, or Wegovy, lost about 33 pounds (15 kilograms). That’s according to the study funded by Lilly, which was published Sunday in the New England Journal of Medicine.

Continue reading

· 13d · on MSN

Zepbound tops Wegovy for weight loss in first head-to-head study comparing the drugs

Health on MSN · 1d

Zepbound or Wegovy? Head-to-Head Trial Says One Is Better for Weight Loss

WXYZ-TV Channel 711d

First head-to-head trial found Zepbound beats Wegovy for weight loss

In today’s Health Alert, two popular weight loss drugs went head-to-head in a clinical trial – and one came out on top.

4don MSN

Weight-loss company Noom pivots to smaller doses of compounded Wegovy

Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy as the U.S.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results